Puma Biotechnology reported mixed trial results By: MarketMinute.com Stock News May 14, 2015 at 19:10 PM EDT Puma Biotechnology Inc. (NYSE: PBYI) reported mixed results for its breast cancer treatment PB272 sending the stock price plummeting $39.05 to close at $170.67.